Replies to post #456472 on Anavex Life Sciences Corp (AVXL)

[Hosai]

"Going to the $40's? Making excuses for the peer review delay? IMO that's a FOMO building pumping post."

He said if we get everything we want i.e peer review and EMA submission/FDA submission which could certainly all be in the next couple of months.
Market would then be a lot more focussed on predicted revenue etc in this massive market (obviously with discount factors for time and chances of approval - this has improved with FDA updated guidance)
I don't see how $40s would be that excessive, $45 a share would put market cap at around $3.7 billion.